Subscribe

News Jun 8, 2020 06:24 pm EqualOcean

BGI Genomics Benefits from Overseas Epidemic, Buying Financial Services with Cash While Raising CNY 500 million in debt

Analysis EO
Analysis · 2
report
Analysis EO
Jul 12, 2020 10:52 am ·

Top 10 Market Cap Chinese Medical Device Companies: Champions and Runners-Up

► Top 10 Chinese medical device companies are selected by market capital. ► Mindray Medical has the highest market cap but is too big to keep R&D-driven. The Chinese A-share market is experiencing a boom, with a record deal value amount at over CNY 1.5 trillion within four trading days. This craze surely has a powerful impact on the medical devices field – a fast-growing business. The medical device industry in China sped up only in recent years due to substantial capital injections, advanced technologies and supportive policies. The current premature stage indicates much potential for growth soon and the exciting emergence of new high-tech companies. A glance at top 10 Chinese medical devices by market cap Here, the top 10 Chinese medical device companies are mentioned, to provide a brief look into local benchmarks in the industry. Some companies have been steadily operating for over 20 years and are recently moving into a new growth stage or reorienting in unprecedented directions due to fierce market competition. Some younger companies have quickly found their value position by advanced resource-upgrading throughout the industry chain. Among the ten companies, there are two clinical medical equipment companies, three high-value medical device providers (such as heart stents, orthopedics implants and ophthalmology), four IVD manufacturers and only one in the home-use medical device area. Based on a general overview of the top ten companies, some companies stand out from the rest. Besides Mindray (300760:SZ), which has the highest market cap, Yuyue Medical (002223:SZ) at 10th position is the only listed home-use medical device company in the top-ten market cap rank.    Mindray: too big to sprint Mindray, the champion company, stands at the top position with an unbeatable valuation of over CNY 380 billion. As suggested by EqualOcean’s fundamental analysis, the company has come this far through frequent acquisitions and strengthening regional distribution channels. The conglomerate provides equipment in life information and support, IVD (in vitro diagnosis) and medical imaging. These three major businesses have been hot picks since the outbreak of COVID-19. However, the conglomerate relies more on the robust R&D foundation and strong global selling network.  When a company gets bigger, the slower the giant grows – an aspect especially indicated by the R&D efficiency. Yuyue: keeping agile in the C-end selling Even though Yuyue medical is ranked 10th in the top ten list, it is the champion company in the home-use medical device segment. One advantage for companies in this segment is that they have more flexibility in selling strategies because they provide end consumers with small medical gadgets, from sphygmomanometers to glucose meters, massage devices, etc. As a previous EqualOcean analysis said, they can not only invest in developing their technology (R & D) but also seek a new growth direction as they shift to a more efficient selling strategy. This is exactly what Yuyue has been trying and will continue to try in the near future. The COVID-19 crisis has created a mania for home healthcare. Yuyue has spared no effort in utilizing this trend. It has been cooperating with the two most prominent e-commerce platforms in China,  Taobao and JD.com. Now the online vendor has an over 1.13 million followers on the Taobao platform alone, with an over 480 thousand sales record of one single SKU (Stock Keeping Unit) – a household digital manometer.

Briefing
Briefing · 1
News
News · 1
News
News · 1
News
Jun 8, 2020 06:46 pm · eastmoney

Buring Rock Will Land on Nasdaq this Friday

News EO
News · 2
report
News EO
May 28, 2020 12:30 pm ·

Chinese Genomics MGI Tech Gets USD 1 Billion in Biotech PE Bullpen

MGI Tech (华大智造), a Shenzhen-based gene sequencing equipment supplier, has completed its Series B financing round, worth USD 1 billion, led by a series of venture capitalists and private equity heavyweights. The firm had previously raised over USD 200 million from Goldstone, Orient Securities and Green Pine Capital  Partners in 2019. The firm was founded as the subsidiary of BGI Group, the parent company of the Chinese genomics heavyweight BGI Genomics (华大基因) (300676:SH). The BGI Group subsidiary has been primarily been producing clinical gene sequencers but has also been providing genetic sequencing, medical imaging, and laboratory automation products and services.  Both MGI Tech and BGI Genomics are strategic companies in China's life sciences and healthcare scene. The sister companies are regarded as the country's first globally-competitive set of genome sequencing companies. Check this in-depth article on how BGI Genomics helped Chinese companies to resume work after Covid-19. Chinese genomics pioneers have used foreign acquisitions in their quest to become competitive in the field, as well. In March 2013, Complete Genomics was acquired by BGI Genomics. In 2018, Complete Genomics became part of MGI, which was the instrument manufacturing business of BGI. Since the beginning of the pandemic, BGI Genomics has initiated a plethora of new businesses and expanded its operational network across geographies. It even received a formal Emergency Use Authorization from the US Food and Drug Administration in March 2020. BGI Genomics' stock price jumped around 100% from CNY 66 levels to CNY 124 between January 1st and May 28 of 2020. Meanwhile, its total revenues reached around USD 394 million in 2019 with approximately 17.8% CAGR from 2012 to 2019. Healthcare, biotech and IT industry-related deals outperformed in private equity markets in the first quarter of 2020 due to the COVID-19 related paradigm shifts.  MGI Tech did not immediately answer EqualOcean's inquiry about this financing round. 

News
News · 1
News
May 21, 2020 10:37 am · BGI Genomics

BGI Genomics to Repurchase Shares with CNY 300 to 600 million

News
News · 1
Briefing
Briefing · 1
Briefing
Briefing · 1
Briefing
Briefing · 1
Briefing
Briefing · 1
Briefing
Briefing · 1
Briefing
Aug 11, 2020 11:04 am · VCBeat

Wallaby Medical in Neuro-intervention Closes Series B+

Briefing
Briefing · 1
Briefing
Aug 10, 2020 06:44 pm · Tonghuashun

Tibet Rhodiola Pharmaceutical Publishes 1H 2020 Financials

Briefing
Briefing · 1
Briefing
Briefing · 1
Briefing
Briefing · 1
Briefing
Briefing · 1
Briefing
Aug 10, 2020 02:01 pm · VCbeat.top

CRO Platform Trial.Link Receives CNY 600 Mn in Series C+ and D

Read more